Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections
5/14/2013 9:58:00 AM
More...
|
Rib-X Pharmaceuticals, Inc. Appoints John E. Sununu to the Board of Directors
5/13/2013 7:18:26 AM
More...
|
Rib-X Pharmaceuticals, Inc. Announces New Executive Leadership and Board of Directors Appointments
4/3/2013 10:50:41 AM
More...
|
Rib-X Pharmaceuticals, Inc. Appoints New Chair of Board of Directors
1/4/2013 6:27:41 AM
More...
|
Rib-X Pharmaceuticals, Inc.' RX-04 Program Will be Featured at Windhover Information Inc.'s Therapeutic Area Partnerships Meeting as a "Top 10 Infectious Diseases Project to Watch"
11/29/2012 9:51:54 AM
More...
|
Rib-X Pharmaceuticals, Inc. Closes $67.5 Million Financing
11/29/2012 7:00:58 AM
More...
|
Rib-X Pharmaceuticals, Inc. Receives Qualified Infectious Disease Product (QIDP) Designation From the FDA for Radezolid
10/10/2012 10:03:36 AM
More...
|
Rib-X Pharmaceuticals, Inc. Receives Qualified Infectious Disease Product (QIDP) Designation From the FDA for Delafloxacin
9/17/2012 9:11:03 AM
More...
|
Rib-X Pharmaceuticals, Inc. Presents Data from Multiple Radezolid Studies at ICAAC Including Successful Intravenous Dosing in Phase 1 and Favorable Long-Term Safety and Tolerability Vs. Linezolid in Vivo
9/12/2012 10:34:58 AM
More...
|
Rib-X Pharmaceuticals, Inc. Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance Against New Objective Endpoints From FDA, From Its Completed Phase 2b Study in Patients With Acute Bacterial Skin and Skin Structure Infections
9/12/2012 10:33:11 AM
More...
|
|